CHRDL2 and tubular adenocarcinoma: By further stratifying analysis, we found that in HER-2-positive female gastric cancer patients with pathological type of tubular adenocarcinoma, all patients with low expression of CHRDL2 had a better prognosis (Figures 3(d)–3(f)).